ADC Therapeutics SA
ADCTNYSE
$1.35
0.0%Jul 17 close · end-of-day
Price
1Y↓ -55.6%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$208.1M
Enterprise Value
-$18.3M
P/E
—
P/S
2.6
P/B
—
EV/EBITDA
—
PEG
—
FCF Yield
-55.1%
Dividend Yield
—
Revenue (TTM)
$79.2M
Net Income (TTM)
-$137.0M
Free Cash Flow (TTM)
-$114.6M
Gross Margin
—
Operating Margin
-149.4%
Net Margin
-173.0%
ROE
63.3%
ROIC
—
Debt / Equity
-0.0
Net Cash
$226.4M
Return 1Y
-56.6%
Company profile
ADC Therapeutics SA develops antibody drug conjugates (ADC) for patients suffering from hematological malignancies and solid tumors. Its flagship product ZYNLONTA that is in Phase II clinical trial for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma. The company is also developing camidanlumab tesirine, an ADC that has completed Phase I clinical trial.
- CEO
- Ameet Mallik
- Sector
- Manufacturing
- Industry
- Pharmaceutical Products
- Employees
- 310
- Website
- adctherapeutics.com
Management & directors
- Carmona JoseChief Financial Officer
- Graham Peter JChief Legal Officer
- Mallik AmeetChief Executive Officer
- Zaki MohamedChief Medical Officer
- Kallebo Lisa MichelleChief Accounting Officer
Roles derived from SEC Form 4 filings.
Earnings
ADCT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$20.9M↓ -9.5%
Diluted EPS-$0.21↓ -41.7%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
| Revenue | $209.9M | $69.6M | $70.8M | $81.4M |
| Gross profit | — | — | — | — |
| Operating income | -$123.3M | -$166.0M | -$130.7M | -$121.5M |
| Net income | -$157.1M | -$240.1M | -$157.8M | -$142.6M |
| Diluted EPS | -$2.01 | -$2.94 | -$1.62 | -$1.12 |
| Operating cash flow | -$138.3M | -$118.7M | -$123.8M | -$141.2M |
| Free cash flow | -$139.0M | -$121.9M | -$124.7M | -$141.4M |
| Gross margin | — | — | — | — |
| Operating margin | -58.8% | -238.6% | -184.4% | -149.3% |
| Net margin | -74.9% | -345.2% | -222.8% | -175.3% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $17.4M | $18.5M | $16.9M | $23.0M | $18.8M | $16.4M | $23.1M | $20.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | -$29.0M | -$35.6M | -$32.4M | -$28.5M | -$44.1M | -$31.0M | -$17.9M | -$25.2M |
| Net income | -$36.5M | -$44.0M | -$30.7M | -$38.6M | -$56.6M | -$41.0M | -$6.4M | -$33.0M |
| Diluted EPS | -$0.38 | -$0.42 | -$0.26 | -$0.36 | -$0.50 | -$0.30 | $0.04 | -$0.21 |
| Operating cash flow | -$32.8M | -$25.0M | -$21.9M | -$56.3M | -$24.1M | -$29.6M | -$31.1M | -$29.7M |
| Free cash flow | -$32.9M | -$25.3M | -$21.9M | -$56.6M | -$24.1M | -$29.6M | -$31.1M | -$29.7M |
| Gross margin | — | — | — | — | — | — | — | — |
| Operating margin | -166.8% | -192.6% | -191.8% | -123.6% | -234.3% | -188.5% | -77.7% | -121.1% |
| Net margin | -209.9% | -238.1% | -181.4% | -167.6% | -300.7% | -249.4% | -27.7% | -158.1% |
Company news
Jun 27, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-30 | MALLIK AMEET· Chief Executive Officer | Award | 675,000 | $0.00 | $0.00 | filing |
| 2026-06-30 | Zaki Mohamed· Chief Medical Officer | Award | 213,900 | $0.00 | $0.00 | filing |
| 2026-06-30 | GRAHAM PETER J· Chief Legal Officer | Award | 221,100 | $0.00 | $0.00 | filing |
| 2026-06-30 | Carmona Jose· Chief Financial Officer | Award | 203,700 | $0.00 | $0.00 | filing |
| 2026-06-03 | Squarer Ron | Tax withholding | 15,196 | $3.08 | $46,803.68 | filing |
| 2026-06-03 | Coughlin Timothy P | Tax withholding | 12,600 | $3.08 | $38,808.00 | filing |
| 2026-06-03 | Azelby Robert | Tax withholding | 12,600 | $3.08 | $38,808.00 | filing |
| 2026-06-03 | Sandor Victor | Tax withholding | 12,600 | $3.08 | $38,808.00 | filing |
| 2026-06-03 | BIZZARI JEAN-PIERRE | Tax withholding | 12,600 | $3.08 | $38,808.00 | filing |
| 2026-06-03 | Monges Viviane | Tax withholding | 2,596 | $3.08 | $7,995.68 | filing |
| 2026-06-03 | Hug Peter | Tax withholding | 2,156 | $3.08 | $6,640.48 | filing |
| 2026-06-01 | Coughlin Timothy P | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | Azelby Robert | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | Squarer Ron | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | Sandor Victor | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | Monges Viviane | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | Hug Peter | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-06-01 | BIZZARI JEAN-PIERRE | Award | 45,000 | $0.00 | $0.00 | filing |
| 2026-04-02 | Redmile Group, LLC | Sale | 2,634,506 | $3.28 | $8.6M | filing |
| 2026-04-02 | Redmile Group, LLC | Sale | 2,529,491 | $3.28 | $8.3M | filing |
| 2026-04-01 | Redmile Group, LLC | Sale | 169,265 | $3.80 | $643,037.74 | filing |
| 2026-04-01 | Redmile Group, LLC | Sale | 162,517 | $3.80 | $617,402.08 | filing |
| 2026-03-31 | Redmile Group, LLC | Sale | 196,229 | $3.75 | $736,251.21 | filing |
| 2026-03-31 | Redmile Group, LLC | Sale | 188,407 | $3.75 | $706,903.06 | filing |
| 2026-02-13 | MALLIK AMEET· Chief Executive Officer | Award | 900,000 | $3.99 | $3.6M | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.